Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 4/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485534 | 0.86 | PTGS1 (0.57) | EGLN1PTGS1PTGS2CYP1A2CYP3A4 | |
| SCHEMBL18883283 | 0.84 | HRH4 (0.40) | TGFBR1EGLN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL16104299 | 0.82 | CLK1 (0.55) | TGFBR1EGLN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL8065354 | 0.82 | TGFBR1 (0.50) | TGFBR1EGLN1PTGS1PTGS2MAPT | |
| SCHEMBL30845741 | 0.82 | EGLN1 (0.52) | TGFBR1EGLN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL12330376 | 0.81 | APP (0.44) | TGFBR1EGLN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL29540016 | 0.81 | PIK3CG (0.56) | TGFBR1EGLN1PTGS1PTGS2CYP1A2 | |
| SCHEMBL3764713 | 0.81 | HRH4 (0.57) | TGFBR1EGLN1MAPTCLK1DYRK1A | |
| SCHEMBL16396042 | 0.80 | RAB9A (0.48) | EGLN1CYP1A2CYP3A4MAPTDYRK1A | |
| SCHEMBL2087802 | 0.79 | PTGS1 (0.46) | EGLN1PTGS1PTGS2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4217347-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-116194445-A | New compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-10463675-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3183247-B9 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3183247-B1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3183247-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | Pfizer Inc (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9663526-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016027195-A1 | AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS | PFIZER INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | TGFBR1 448/4885EGLN1 2060/4885PTGS1 117/4885 |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | TGFBR1 731/4885EGLN1 176/4885PTGS1 75/4885 |
| US-20240043450-A1 | NEW COMPOUND | NLRP3, NLRP1, PYCARD | TGFBR1 1302/4885EGLN1 1414/4885PTGS1 594/4885 |
| US-10463675-B2 | Aminopyrimidinyl compounds | JAK2, JAK1, JAK3 | TGFBR1 1390/4885EGLN1 2244/4885PTGS1 1886/4885 |
| US-20200038409-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | TGFBR1 794/4885EGLN1 3562/4885PTGS1 4353/4885 |
| US-20170239264-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | TGFBR1 794/4885EGLN1 3562/4885PTGS1 4353/4885 |
| US-20160052930-A1 | AMINOPYRIMIDINYL COMPOUNDS | CNKSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | TGFBR1 794/4885EGLN1 3562/4885PTGS1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.